- Merck KGaA Drops Heart Drug After Novartis Trial Failure Raises Concerns
Merck KGaA plans to drop an experimental heart drug it’s acquiring through the takeover of Silence Therapeutics Plc in the wake of the failure of a similar treatment by rival Novartis AG.
Product·1 article / 1 outlet·3d ago
- Merck KGaA Raises Full-Year Earnings Outlook for Third Time on Lab-Equipment Strength
Merck KGaA raised its full-year earnings outlook for a third time, helped by a strong performance in its lab-equipment division and a slower-than-expected decline in sales of its multiple sclerosis drug Mavenclad.
Guidance·1 article / 1 outlet·3d ago
- MSF Urges Wider Use of Merck’s Ervebo Ebola Vaccine in Congo Outbreak
Merck & Co.’s Ebola vaccine should be deployed more widely in the Democratic Republic of Congo’s escalating outbreak, Doctors Without Borders said, citing emerging evidence that the shot may provide protection against a virus it wasn’t designed to target.
Product·1 article / 1 outlet·6d ago
- Merck Raises Profit Outlook After Keytruda Sales Exceed Expectations↩
Merck & Co. raised its full-year profit forecast after third-quarter results topped Wall Street’s expectations, fueled by stronger-than-anticipated sales of cancer blockbuster Keytruda and other newer medicines.
Earnings·1 article / 1 outlet·17d ago
- Moderna, Merck Investors Clash With Oncologists Over Cancer Drugs
Investors in Moderna and Merck are at odds with oncologists regarding the future of cancer drugs. The debate centers on differing perspectives on the development and investment in these pharmaceuticals.
Macro·1 article / 1 outlet·17d ago
- Merck Tops Quarterly Estimates, Hikes 2026 Profit Outlook on Keytruda Strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Macro·2 articles / 2 outlets·17d ago
- Moderna CEO Confident Cancer Vaccines Will Work Beyond Melanoma
Moderna Inc. Chief Executive Officer Stephane Bancel said he believes the personalized mRNA cancer vaccine his company is developing with Merck & Co. will work in a variety of tumors, directly addressing a key issue shrouding the company’s future.
Product·2 articles / 2 outlets·20d ago
- Merck Drug Cuts Death Risk By One-Third In Advanced Endometrial Cancer
An experimental drug from Merck & Co. helped women with advanced endometrial cancer live significantly longer than those receiving chemotherapy.
Product·2 articles / 2 outlets·20d ago
- Moderna And Merck Shares Fall After Cancer Vaccine Results Show Limited Efficacy
Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker's experimental cancer treatment.
Product·2 articles / 2 outlets·20d ago
- Moderna And Merck's mRNA Cancer Vaccine Validated By Melanoma Research
Study findings validate a novel approach for fighting deadly skin cancer, while its potential in other tumors remains unproved.
Product·1 article / 1 outlet·20d ago
- Moderna and Merck's Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
Moderna and Merck's personalized mRNA cancer vaccine reduced melanoma recurrence risk by 42%. The data, released at ESMO, showed improvements in recurrence-free survival and delayed onset of distant metastasis.
Product·2 articles / 2 outlets·20d ago
- Moderna Shares Plummet 17% After Leaked Cancer Vaccine Data Misses Expectations↩
Moderna and Merck experienced significant stock declines following the leak of data regarding their personalized melanoma vaccine. The treatment demonstrated a 58% reduction in the risk of recurrence or death, but failed to meet Wall Street's high expectations, leading to a sell-off in both companies' shares.
Product·2 articles / 2 outlets·23d ago
